Rakuten Aspyrian

Website:rakutenaspyrian.com
Location:San Diego, CA United States
Revenue:$20.3M
Industry:Biotech
Founded:N/A
Lead Investor(s):SBI Group, Rakuten
Press

Current Growjo Ranking

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Rakuten Aspyrian, Inc., is a privately funded clinical stage biotechnology company with offices in the USA, Japan and Germany. Since 2013, Rakuten Aspyrian has been developing new anticancer therapies based on the Photoimmunotherapy platform. Rakuten Aspyrian plans to become a fully integrated biopharma with research, development, and world-wide commercialization of therapies based on the Photoimmunotherapy platform. Our long-term objective is to commercialize a number of therapies based on Photoimmunotherapy to treat a broad range of solid tumor types as single agent and in combination with other immunomodulatory agents to generate robust and long lasting anticancer immunological responses. Rakuten Aspyrian is currently sponsoring a global Phase 3 multicenter clinical study for ASP-1929 to evaluate the efficacy and safety of ASP-1929 in patients with recurrent Head and Neck Cancer and additional Phase 2 studies to evaluate the safety and efficacy of ASP-1929 in patients with other cancer types. Given the rapid progression of the clinical studies, we are quickly expanding the team to support late stage pivotal clinical development and future commercialization of our products.

keywords:N/A

96

Number of Employees

$20.3M

Revenue (est)

19

Current Jobs

100%

Employee Growth %

$351.8M

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type

Rakuten Aspyrian News

28-Feb-19 - Rakuten Aspyrian Announces Name Change to Rakuten Medical

SAN MATEO, Calif., March 1, 2019 /PRNewswire/ -- Rakuten Aspyrian, a biotechnology company developing precision-targeted cancer

2-Mar-19 - Camille Roberts, Jaryd Lindheim

Her mother, an oncology nurse practitioner, is based in Nashville as a field clinical trainer at Rakuten Aspyrian, a clinical stage biotechnology

25-Feb-19 - Top 10 Immuno-Oncology Startups

Rakuten Aspyrian completed a two-tranche, $284 million Series C round last year. Proceeds will support the company's Phase III ASP-1929

Rakuten Aspyrian Funding

DateAmountRoundLead InvestorsReference
2018-08-24$150.0MCRakuten IncArticle
2018-12-21$134.0MCSBI GroupArticle

Rakuten Aspyrian Executive Hires

DateNameTitleReference
2018-11-15Mickey MikitaniCEO, chairmanArticle